

SHORT REPORT

Partial duplications of the *MSH2* and *MLH1* genes in hereditary nonpolyposis colorectal cancer

Stephanie Baert-Desurmont¹, Marie-Pierre Buisine², Emilie Bessenay¹, Stephanie Frerot¹, Tonio Lovecchio², Cosette Martin¹, Sylviane Olschwang³, Qing Wang⁴ and Thierry Frebourg^{*,1}

¹Inserm U614, Faculty of Medicine, Rouen, France and Department of Genetics, Rouen University Hospital, Rouen, France; ²Oncology and Molecular Genetics, Lille University Hospital, Lille, France; ³Inserm U599, Institut Paoli-Calmettes, Marseille, France; ⁴Molecular Oncology, Centre Léon Bérard, Lyon, France

Numerous reports have highlighted the contribution of *MSH2* and *MLH1* genomic deletions to hereditary nonpolyposis colorectal cancer (HNPCC) or Lynch's syndrome, but genomic duplications of these genes have been rarely reported. Using quantitative multiplex PCR of short fluorescent fragments (QMPSF), 962 and 611 index cases were, respectively, screened for *MSH2* and *MLH1* genomic rearrangements. This allowed us to detect, in 11 families, seven *MSH2* duplications affecting exons 1–2–3, exons 4–5–6, exon 7, exons 7–8, exons 9–10, exon 11, and exon 15, and three *MLH1* duplications affecting exons 2–3, exon 4 and exons 6–7–8. All duplications were confirmed by an independent method. The contribution of genomic duplications of *MSH2* and *MLH1* to HNPCC can therefore be estimated approximately to 1% of the HNPCC cases. Although this frequency is much lower than that of genomic deletions, the presence of *MSH2* or *MLH1* genomic duplications should be considered in HNPCC families without detectable point mutations.

European Journal of Human Genetics (2007) 15, 383–386. doi:10.1038/sj.ejhg.5201765; published online 17 January 2007

Keywords: HNPCC; Lynch's syndrome; *MSH2*; *MLH1*; QMPSF; duplication

Introduction

Hereditary nonpolyposis colorectal cancer (HNPCC) or Lynch's syndrome, which represents the most common form of inherited colorectal cancer, results from germline alterations of the DNA mismatch repair genes *MSH2*, *MLH1*, *MSH6* and *PMS2* (for review see Gruber¹). Identification of the causal alteration is essential for an appropriate clinical management of the families as it allows to offer to carriers an efficient tumour detection, based on colonoscopy and hysteroscopy every 2 years from 20 years of age and to avoid an inappropriate follow-up in noncarriers. Point mutations within *MSH2*, *MLH1*, and *MSH6* account approximately for 25, 25 and less than 5% of the HNPCC families, respectively. Numerous reports, initially based on

Southern blot or RT-PCR, then on QMPSF (Quantitative Multiplex PCR of Short Fluorescent Fragments), MLPA (Multiplex Ligation-dependent Probe Amplification) or conversion analysis have now underlined the significant contribution of *MSH2* and *MLH1* genomic deletions to HNPCC.^{2–24} At present, 43 *MSH2* and 33 *MLH1*, distinct exonic deletions, removing either a single or multiple exons, have been reported.^{2–24} We previously estimated that genomic deletions of *MSH2* and *MLH1* respectively, account for approximately 10 and 4% of HNPCC families fulfilling Amsterdam criteria.^{6,13} All the *MSH2* genomic deletions detected so far have been shown to result from unequal *Alu*-mediated recombinations^{6,8,11,12,18,20} and we found that the density of *Alu S* repeats within the *MSH2* 5' region was remarkably high, compared with other human genes.¹⁸ In contrast, *MLH1* genomic deletions have been found to involve not only *Alu* repeats, but also nonhomologous sequences.^{2,3,9,20,21} As expected, exonic *MSH2* and *MLH1* duplications, the reciprocal genomic alterations of deletions resulting from unequal crossingover, have also

*Correspondence: Dr T Frebourg, Inserm U614, Faculty of Medicine, 22 Boulevard Gambetta, 76183 Rouen, France. Tel: +33 02 32 88 81 82; Fax: 02 32 88 80 80; E-mail: frebourg@chu-rouen.fr
Received 25 July 2006; revised 16 November 2006; accepted 21 November 2006; published online 17 January 2007

been detected in HNPCC families, but at a much lower frequency. We reported, using QMPFSF, the first case of a *MSH2* duplication involving exons 9–10 that was confirmed by long-range PCR⁵ and we subsequently detected another *MSH2* duplication involving exons 7–8.¹³ Only eight other *MMR* duplications have been reported in studies based either on MLPA or conversion analysis: for *MSH2*, duplication of exons 5–6,¹⁹ exon 7,¹⁵ exons 11–16;¹⁷ for *MLH1*, duplication of exon 1,¹⁶ exon 3,¹⁶ exon 19,¹⁶ exons 6–12,¹⁹ and exons 7–12.²⁵ We now report the detection of 10 *MSH2* and *MLH1* exonic duplications, 7 of which are novel. The aim of this report was to highlight the contribution to HNPCC of *MMR* genomic duplications and to estimate the frequency of these alterations.

Materials and methods

Patients

Patients analysed in this study, either fulfilled Amsterdam (AMS) criteria (at least three relatives with colorectal cancer, cancer of the endometrium, small bowel, ureter or renal pelvis, one of whom is a first-degree relative of the other two; at least two successive generations affected; and at least one cancer diagnosed before age 50²⁶) or were selected because of a suggestive familial history associated to a microsatellite instability (MSI) phenotype in the tumour. A total of 962 and 611 index cases were, respectively, screened for *MSH2* and *MLH1* genomic rearrangements.

QMPFSF analysis

The QMPFSF protocol used to screen for genomic rearrangements of *MSH2* and *MLH1* has been described previously.^{5,6} Briefly, short fragments corresponding to the 16 *MSH2* and 19 *MLH1* exons and to control genes, were simultaneously PCR-amplified using dye-labeled primers. Primer sequences are available upon request. PCR products were separated by electrophoresis on an ABI-377 or 3100 automated sequencer (Applied Biosystems, Foster, USA). Data were analysed using the Gene Scanner Model 672 Fluorescent Fragment Analyzer (Applied Biosystems, Foster, USA). For each index case, QMPFSF profile was superposed to that generated from a control-DNA by adjusting to the same level the peaks obtained for the control amplicon. Based on an extensive number of QMPFSF analyses (including >50 genes and >1000 tests) performed in our laboratory, we have estimated the variability of gene copy number measurements to be 0.1 among control samples. Thus, copy number ratios between 0.9 and 1.1 indicate two gene copies, and copy number ratios between 1.4 and 1.6 indicate three copies.^{5,27–29} Each positive result was confirmed by another QMPFSF analysis performed on an independent sample.

MLPA

MLPA was performed using the SALSA P003 (*MLH1/MSH2*) MLPA kit (MRC Holland, Amsterdam, The Netherlands)

according to the manufacturer's protocol. Fragments were separated and analyzed with a 377XL genetic analyzer and Genescan 3.1 software as well as with a 3100-Avant capillary genetic analyzer and GeneMapper 3.5 software (Applied Biosystems). Peak areas and heights were then exported to a Microsoft Excel spreadsheet (http://leedsdna.info/science/dosage/Conventional_MLPA/Conventional_MLPA.htm) and calculations were carried out according to the method described by Taylor *et al.*¹⁰

Results

Using QMPFSF, we detected 10 distinct genomic duplications of *MSH2* or *MLH1* genes in 11 families: seven duplications involved *MSH2* exons 1–2–3, exons 4–5–6, exon 7, exons 7–8, exons 9–10, exon 11, and exon 15, and three duplications involved *MLH1* exons 2–3, exon 4 and exons 6–7–8 (Table 1). As illustrated by Figure 1, exonic duplications could easily be detected by QMPFSF by a 1.5 increase of the corresponding peaks. Only the duplication of *MSH2* exons 9–10 detected in family L14 had previously been confirmed by long-range PCR.⁵ MLPA was therefore used in the present study to confirm the nine other duplications. In each case, MLPA confirms the presence of the exonic duplication(s) detected by QMPFSF. These duplications generate in MLPA an increase of the corresponding peak area(s) above 1.3. In one family (G1), we observed a discrepancy between QMPFSF and MLPA concerning the extent of duplication. Indeed, QMPFSF revealed the presence of a *MSH2* duplication involving exons 5–6, whereas MLPA suggested that this duplication also involved exon 4. In order to clarify the situation, we designed new QMPFSF assays exploring specifically intron 3, exon 4 and intron 4 of *MSH2*. These complementary QMPFSF analyses revealed that, within the G1 family, the duplication included exon 4, but did not extend to nucleotide c.646–121 corresponding to the sense primer used in the first QMPFSF assay, and therefore did not involve the first 1920 nucleotides of intron 3.

Discussion

One hypothesis that might explain the difference in the numbers of *MMR* genes genomic deletions and duplications reported so far is the technical difficulty to detect duplications *versus* deletions. Indeed, the largest series of HNPCC patients screened for *MMR* genomic rearrangements have been analysed using QMPFSF¹³ or MLPA.¹⁹ In both methods, heterozygous deletions result in a 0.5 reduction of the corresponding peaks, whereas duplications generate a 1.5 increase. This could explain why duplications are more difficult to detect than deletions, and this might represent a technical bias in the estimation of *MMR* duplications frequency. QMPFSF analysis allowed us in this large series of suspected HNPCC patients to detect

Table 1 Duplications of *MSH2* or *MLH1* in HNPCC families

Family	Duplicated gene	Duplicated exon(s)	Amsterdam criteria	Earliest age of tumour onset (in years)
R1	<i>MSH2</i>	Exons 1–2–3	+	52
G1		Exons 4–5–6	+	42
B1		Exon 7 ^a	+	42
S1 ^b		Exons 7–8	—	45
L14 ^b		Exons 9–10	+	37
B2		Exons 9–10	+	49
R2		Exon 11	—	30
M2		Exon 15	+	42
M1	<i>MLH1</i>	Exons 2–3	+	28
SC1		Exon 4	—	38
G2		Exons 6–7–8	+	45

^aThis duplication has already been detected by Casey *et al.*¹⁵

^bWe already reported this family.^{5,13}




Figure 1 Detection by QMPFS of duplications of the *MSH2* and *MLH1* genes. The left panels show the QMPFS electropherograms in four families and the right panels the results of the corresponding MLPA analyses. In each QMPFS panel, the electropherogram of the patient (in red) was superimposed to that of a normal control (in blue) by adjusting to the same level the peaks obtained for the control (C) amplicon. The Y-axis displays fluorescence in arbitrary units, and the X-axis indicates the size in bp. *MSH2* or *MLH1* exons are indicated. Lines indicate the top of the normal blue peak. Duplications are detected by a 1.5 increase of the peaks compared with a normal control. (a) Detection of an *MSH2* exon 11 duplication in family R2; (b) Detection of an *MSH2* exon 15 duplication in family M2; (c) detection of an *MLH1* exons 2 and 3 duplication in family M1; (d) detection of an *MLH1* exons 6, 7 and 8 duplication in family G2.

10 distinct *MSH2* or *MLH1* partial genomic duplications, which were all confirmed by another independent method. This shows, as previously illustrated for the *BRCA1*,²⁷ *BRCA2*,²⁸ and *APP* genes,²⁹ that QMPFS is a reliable method for the detection of genomic duplications. Although we cannot provide in this study an accurate estimation of the contribution of *MSH2* and *MLH1* duplications to HNPCC, as the population analysed was heterogeneous including both AMS+ patients and AMS- patients with an MSI phenotype in the tumour, the frequency of *MSH2* and *MLH1* duplications appears low. In our series, 962 and 611 index cases were, respectively, screened for *MSH2* and *MLH1* genomic rearrangements. This allowed us to detect, in 115 families, 30 and 18 distinct exonic deletions of *MSH2* and *MLH1*, respectively (Charbonnier *et al.*¹⁸ and unpublished results). In contrast, in the same series, we detected in 11 families, 7 and 3 exonic duplications of *MSH2* and *MLH1*. Therefore, *MSH2* and *MLH1* duplications account probably for approximately 1% of the HNPCC cases. Although genomic duplications of *MSH2* and *MLH1* are less frequent than genomic deletions, their presence should nevertheless be considered in HNPCC families without detectable point mutations.

Acknowledgements

We thank our colleagues from the French HNPCC consortium, especially Pascaline Berthet, Olivier Caron, Philippe Gorry, Dominique Leroux, Michel Longy, Rosette Lidereau. This work was supported by a grant from the French National Cancer Institute (INCA) to the Northwest Canceropole.

References

- Gruber SB: New developments in Lynch syndrome (hereditary nonpolyposis colorectal cancer) and mismatch repair gene testing. *Gastroenterology* 2006; **130**: 577–587.
- Nystrom-Lahti M, Kristo P, Nicolaides NC *et al*: Founding mutations and Alu-mediated recombination in hereditary colon cancer. *Nat Med* 1995; **1**: 1203–1206.
- Mauillon JL, Michel P, Limacher JM *et al*: Identification of novel germline hMLH1 mutations including a 22 kb Alu-mediated deletion in patients with familial colorectal cancer. *Cancer Res* 1996; **56**: 5728–5733.
- Wijnen J, van der Klift H, Vasen H *et al*: *MSH2* genomic deletions are a frequent cause of HNPCC. *Nat Genet* 1998; **20**: 326–328.
- Charbonnier F, Raux G, Wang Q *et al*: Detection of exon deletions and duplications of the mismatch repair genes in hereditary nonpolyposis colorectal cancer families using multiplex polymerase chain reaction of short fluorescent fragments. *Cancer Res* 2000; **60**: 2760–2763.
- Charbonnier F, Olschwang S, Wang Q *et al*: *MSH2* in contrast to *MLH1* and *MSH6* is frequently inactivated by exonic and promoter rearrangements in hereditary nonpolyposis colorectal cancer. *Cancer Res* 2002; **62**: 848–853.
- Gille JJ, Hogervorst FB, Pals G *et al*: Genomic deletions of *MSH2* and *MLH1* in colorectal cancer families detected by a novel mutation detection approach. *Br J Cancer* 2002; **87**: 892–897.
- Nakagawa H, Hampel H, de la Chapelle A: Identification and characterization of genomic rearrangements of *MSH2* and *MLH1* in Lynch syndrome (HNPCC) by novel techniques. *Hum Mutat* 2003; **22**: 258.
- Viel A, Petronzelli F, Della Puppa L *et al*: Different molecular mechanisms underlie genomic deletions in the *MLH1* Gene. *Hum Mutat* 2002; **20**: 368–374.
- Taylor CF, Charlton RS, Burn J, Sheridan E, Taylor GR: Genomic deletions in *MSH2* or *MLH1* are a frequent cause of hereditary non-polyposis colorectal cancer: identification of novel and recurrent deletions by MLPA. *Hum Mutat* 2003; **22**: 428–433.
- Wang Y, Friedl W, Lamberti C *et al*: Hereditary nonpolyposis colorectal cancer: frequent occurrence of large genomic deletions in *MSH2* and *MLH1* genes. *Int J Cancer* 2003; **103**: 636–641.
- Wagner A, Barrows A, Wijnen JT *et al*: Molecular analysis of hereditary nonpolyposis colorectal cancer in the United States: high mutation detection rate among clinically selected families and characterization of an American founder genomic deletion of the *MSH2* gene. *Am J Hum Genet* 2003; **72**: 1088–1100.
- Di Fiore F, Charbonnier F, Martin C *et al*: Screening for genomic rearrangements of the MMR genes must be included in the routine diagnosis of HNPCC. *J Med Genet* 2004; **41**: 18–20.
- Bunyan DJ, Eccles DM, Sillibourne J *et al*: Dosage analysis of cancer predisposition genes by multiplex ligation-dependent probe amplification. *Br J Cancer* 2004; **91**: 1155–1159.
- Casey G, Lindor NM, Papadopoulos N *et al*: Conversion analysis for mutation detection in *MLH1* and *MSH2* in patients with colorectal cancer. *JAMA* 2005; **293**: 799–809.
- Zhu M, Li J, Zhang X *et al*: Large genomic aberrations in *MSH2* and *MLH1* genes are frequent in Chinese colorectal cancer. *Cancer Genet Cytogenet* 2005; **160**: 61–67.
- Castellvi-Bel S, Castells A, Strunk M *et al*: Genomic rearrangements in *MSH2* and *MLH1* are rare mutational events in Spanish patients with hereditary nonpolyposis colorectal cancer. *Cancer Lett* 2005; **225**: 93–98.
- Charbonnier F, Baert-Desurmont S, Liang P *et al*: The 5' region of the *MSH2* gene involved in hereditary non-polyposis colorectal cancer contains a high density of recombinogenic sequences. *Hum Mutat* 2005; **26**: 255–261.
- Baudhuin LM, Ferber MJ, Winters JL *et al*: Characterization of hMLH1 and hMSH2 gene dosage alterations in Lynch syndrome patients. *Gastroenterology* 2005; **129**: 846–854.
- Li L, McVety S, Younan R *et al*: Distinct patterns of germ-line deletions in *MLH1* and *MSH2*: the implication of Alu repetitive element in the genetic etiology of Lynch syndrome (HNPCC). *Hum Mutat* 2006; **27**: 388.
- McVety S, Li L, Thiffault I *et al*: The value of multi-modal gene screening in HNPCC in Quebec: three mutations in mismatch repair genes that would have not been correctly identified by genomic DNA sequencing alone. *Fam Cancer* 2006; **5**: 21–28.
- Spaepen M, Vankeirsbilck B, Van Opstal S *et al*: Germline Mutations of the hMLH1 and hMSH2 Mismatch Repair Genes in Belgian Hereditary Nonpolyposis Colon Cancer (HNPCC) Patients. *Fam Cancer* 2006; **5**: 179–189.
- Kurawski G, Suchy J, Lener M *et al*: Germline *MSH2* and *MLH1* mutational spectrum including large rearrangements in HNPCC families from Poland (update study). *Clin Genet* 2006; **69**: 40–47.
- Niessen RC, Berends MJ, Wu Y *et al*: Identification of mismatch repair gene mutations in young colorectal cancer patients and patients with multiple HNPCC-associated tumours. *Gut* 2006; **55**: 1781–1788.
- Nakagawa H, Yan H, Lockman J *et al*: Allele separation facilitates interpretation of potential splicing alterations and genomic rearrangements. *Cancer Res* 2002; **62**: 4579–4582.
- Vasen HF, Watson P, Mecklin JP, Lynch HT: New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative group on HNPCC. *Gastroenterology* 1999; **116**: 1453–1456.
- Casilli F, Di Rocco ZC, Gad S *et al*: Rapid detection of novel *BRCA1* rearrangements in high-risk breast-ovarian cancer families using multiplex PCR of short fluorescent fragments. *Hum Mutat* 2002; **20**: 218–226.
- Tournier I, Paillerets BB, Sobol H *et al*: Significant contribution of germline *BRCA2* rearrangements in male breast cancer families. *Cancer Res* 2004; **64**: 8143–8147.
- Rovelet-Lecrux A, Hannequin D, Raux G *et al*: *APP* locus duplication causes autosomal dominant early-onset Alzheimer disease with cerebral amyloid angiopathy. *Nat Genet* 2006; **38**: 24–26.